Pharmafile Logo
Pharmafocus logo
Advanced Search

zealand

Showing 3 posts of 3 posts found.

david_horn_solomon

Silence Therapeutics appoints ex-Akari CEO in top position

July 17, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Akari, CEO, Sanofi, Silence Therapeutics, zealand

Silence Therapeutics has appointed Dr David Horn Solomon as its new Chief Executive Officer (CEO), effective immediately. Solomon will head …

Appointment
sanofi_multaq

FDA delays appraisal of Sanofi, Zealand diabetes drug just days before decision due

August 22, 2016
Research and Development, Sales and Marketing NDA, Sanofi, appraisal, diabetes, iglarlixi, type 2, type-2, zealand

There was unfortunate news for Sanofi and Zealand Pharma as the FDA announced that it required additional information, constituting a …

News
sanofi_hq__boetie_hall

Sanofi gets FDA approval for type-2 diabetes treatment Adlyxin

July 28, 2016
Research and Development, Sales and Marketing FDA, Lixisenatide, Lyxumia, Sanofi, adlyxin, approval, diabetes, type 2, type-2, zealand

Sanofi has announced that the US Food and Drug Administration (FDA) has approved Adlyxin (lixisenatide), which is a once-daily mealtime …

News

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023